Celularity Inc., (CELU): Price and Financial Metrics
GET POWR RATINGS... FREE!
CELU Stock Price Chart Interactive Chart >
CELU Price/Volume Stats
|Current price||$8.91||52-week high||$13.40|
|Prev. close||$8.51||52-week low||$3.63|
|Day high||$8.96||Avg. volume||270,789|
|50-day MA||$9.23||Dividend yield||N/A|
|200-day MA||$7.03||Market Cap||1.23B|
Celularity Inc., (CELU) Company Bio
Celularity Inc., a clinical stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies. The company is developing unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR, and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious diseases, and degenerative diseases. It also develops and manufactures biomaterials derived from the postpartum placenta. The company was founded in 2016 and is based in Florham Park, New Jersey.
Most Popular Stories View All
CELU Latest News Stream
|Loading, please wait...|
CELU Latest Social Stream
View Full CELU Social Stream
Latest CELU News From Around the Web
Below are the latest news stories about Celularity Inc that investors may wish to consider to help them evaluate CELU as an investment opportunity.
Celularity (CELU) is a clinical-stage biotech company at the frontier of some of the world’s most cutting-edge cancer research. The company’s innovative use of placental tissue as material for its NK-cell and T-cell therapies may prove more effective and cost-efficient than alternative allogeneic sources, which have traditionally been limited to iPSC, umbilical cord blood and healthy-donor peripheral blood. Oppenheimer analyst Matthew Biegler is of the belief that allogeneic NK-cell and T-cell therapies are on their way to replacing autologous CAR-T, citing “improvements in scalability, accessibility, and performance.
Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need Phase 1/2a clinical trial will evaluate the safety and preliminary efficacy of CYNK-101 in combination with standard chemotherapy, trastuzumab and pembrolizumab as a first-line treatment in advanced HER2/neu positive gastric and gastroesophageal junction cancer Fifth designation received by Celularity within twelve months f
New York, NY, based Investment company C V Starr & Co Inc (Current Portfolio) buys Celularity Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, C V Starr & Co Inc.
Zug, V8, based Investment company Starr International Co Inc (Current Portfolio) buys Celularity Inc, sells Moderna Inc, AstraZeneca PLC, Johnson & Johnson during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Starr International Co Inc.
The FDA has granted Fast Track designation to Antares Pharma Inc''s (NASDAQ: ATRS ) for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using Vai proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone. The
CELU Price Returns